ArticleBMC plant biology2025
Elucidating the growth-promoting factors of Bacillus amyloliquefaciens on rapeseed through metabolomics.
Article in BMC plant biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Roles of Metabolites Unveiled by Metabolomics inMetabolites · 2026Review
- Plant Growth-Promoting Microorganisms Mediate Plant Metabolic Reprogramming to Manage the Rhizospheric Microbiome.Microorganisms · 2026Review
- Combined effects of earthworms andFrontiers in microbiology · 2026Article
- Correction: Elucidating the growth-promoting factors of Bacillus amyloliquefaciens on rapeseed through metabolomics.BMC plant biology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
backgroundPlant Growth-Promoting Rhizobacteria (PGPR), such as Bacillus amyloliquefaciens, play vital roles in enhancing plant growth and stress tolerance. This study aims to evaluate the effects of the B. amyloliquefaciens strain Bam22 on the growth and metabolic profile of rapeseed (Brassica napus) seedlings, specifically focusing on uncovering the underlying metabolic mechanisms.
resultsInoculation with Bam22 significantly promoted rapeseed growth. Compared to the control, plant height increased by approximately 17.1% and root length by 14.4% at 35 days post-inoculation (dpi). While leaf number remained no significant changed, fresh weight showed significant increases of approximately 70.3% (shoot, 7 dpi), 39.4% (shoot, 35 dpi), 23.8% (root, 7 dpi), and 26.8% (root, 35 dpi), respectively. Wide-targeted metabolomic analysis using UPLC-MS/MS detected 1,785 metabolites. Statistical analysis revealed significant time-dependent metabolic shifts. After 7 days, 192 metabolites were significantly up-accumulated, with notable enrichment in flavonoids (particularly flavonols, e.g., sophoraflavonoloside, FC = 3.39) and phenolic acids. At 35 dpi, 135 metabolites were up-accumulated, with significant enrichment in lipids (predominantly lysophosphatidylcholines-LPCs and lysophosphatidylethanolamines-LPEs) and flavonoids. Crucially, Bam22 induced a profound and directed reprogramming of flavonoid metabolism. Key changes included enhanced flux towards naringenin chalcone synthesis and the accumulation of specific anthocyanin precursors (e.g., cyanidin 3-O-glucoside, delphinidin 3-O-glucoside) and flavonols (e.g., Kaempferol-O-sophoroside).
conclusionsThis study provides the first report linking a B. amyloliquefaciens strain to systemic reprogramming of the flavonoid metabolome in rapeseed, revealing its role as a key mechanism underlying PGPR-induced growth enhancement. This flavonoid-centric metabolic shift, potentially enhancing stress tolerance (e.g., UV protection) and facilitating beneficial plant-microbe communication, provides crucial mechanistic insights into plant-microbe interactions and highlights the potential of targeting flavonoid metabolism for developing Bam22-based biofertilizers to optimize rapeseed productivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.